1 2 3 4 5 6 7 9 17 24 32

SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa

  • Ongoing clinical trials of nanrilkefusp alfa will be discontinued due to insufficient efficacy;
  • SOTIO plans to explore combinations of nanrilkefusp alfa with other modalities;
  • SOTIO to continue to advance its immunocytokine platform including next-generation SOT201 program.

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

  • Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population.
  • Phase 1/2 study is evaluating SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers.

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.